The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01029002|
Recruitment Status : Completed
First Posted : December 9, 2009
Last Update Posted : February 16, 2015
|Condition or disease||Intervention/treatment||Phase|
|Chronic Renal Insufficiency Proteinuria||Drug: Vitamin D Other: Placebo||Phase 3|
This RCT will enroll 75 subjects, men and women over age of 18, with stage 3-4 CKD from various causes including diabetes and hypertension. Patients will be recruited from the Montefiore Medical Center Nephrology clinics and the Montefiore Medical Center internal medicine clinics and other interested individuals.
Informed consent will be obtained on all subjects. All subjects with meet with one of the investigators who will verbally explain to them the purpose of the study and the alternatives.
Blood and urine tests will be collected to assess for proteinuria, vitamin D levels, serum creatinine, calcium and phosphorus, as well as a urine albumin, calcium and creatinine. These tests will be used for experimental purposes only and will be collected at each study visit over the span of 6 months.
There will be two arms, an arm randomized to 50000IU of ergocalciferol once weekly and a placebo arm for 3 months. For an additional 3 months, all patients will be repleted with Vitamin D via open-label extension, based on their levels after 3 months.
Secondary outcomes include ambulatory blood pressure monitoring, hemoglobin A1c, HOMA-IR.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||75 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease|
|Study Start Date :||October 2009|
|Primary Completion Date :||June 2014|
|Study Completion Date :||June 2014|
Experimental: Vitamin D 50000 IU
Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
Drug: Vitamin D
Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
Placebo Comparator: Placebo
Patients randomized to this arm will receive a placebo pill once weekly.
Patients randomized to this arm will receive one placebo pill once weekly.
- To assess the effect of vitamin D supplementation on albuminuria in CKD patients as assessed by urine albumin/creatinine measures. [ Time Frame: 3 months ]
- To assess whether repletion doses of vitamin D increase 25(OH) vitamin D levels to above 30 ng/mL in a multi-ethnic sample of patients with CKD as a secondary outcome. [ Time Frame: 3 months ]
- To assess the effect of vitamin D supplementation on mean systolic blood pressure as measured by ambulatory blood pressure in CKD patients as a secondary outcome. [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01029002
|United States, New York|
|Montefiore medical center|
|Bronx, New York, United States, 10467|
|Principal Investigator:||Michal Melamed, MD, MHS||Albert Einstein College of Medicine, Inc.|